Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EPS (Basic): 2014-2024

Historic EPS (Basic) for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to -$127.21.

  • Spyre Therapeutics' EPS (Basic) rose 85.87% to -$5.97 in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.07, marking a year-over-year increase of 87.71%. This contributed to the annual value of -$127.21 for FY2024, which is 76.88% up from last year.
  • Spyre Therapeutics' EPS (Basic) amounted to -$127.21 in FY2024, which was up 76.88% from -$550.29 recorded in FY2023.
  • Spyre Therapeutics' EPS (Basic)'s 5-year high stood at -$1.52 during FY2020, with a 5-year trough of -$550.29 in FY2023.
  • For the 3-year period, Spyre Therapeutics' EPS (Basic) averaged around -$234.12, with its median value being -$127.21 (2024).
  • Per our database at Business Quant, Spyre Therapeutics' EPS (Basic) crashed by 2,113.56% in 2023 and then surged by 76.88% in 2024.
  • Yearly analysis of 5 years shows Spyre Therapeutics' EPS (Basic) stood at -$1.52 in 2020, then crashed by 1,546.05% to -$25.02 in 2021, then increased by 0.64% to -$24.86 in 2022, then plummeted by 2,113.56% to -$550.29 in 2023, then soared by 76.88% to -$127.21 in 2024.